Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDM-06 is an investigational small interfering RNA (siRNA) therapy being developed by Sirius Therapeutics for the treatment of heart failure. As part of the company's cardiometabolic pipeline, SRNDM-06 utilizes siRNA-mediated gene silencing to modulate a specific, currently undisclosed molecular target associated with heart failure pathology. The drug is designed to be delivered using Sirius's proprietary delivery platforms, which are capable of targeting tissues including the liver, adipose, heart, kidney, or central nervous system. It is currently in the pre-clinical/IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDM-06.